| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
The compound does not target a specific protein; rather, it is a lipid-based delivery vehicle (transfection reagent) used to transport negatively charged nucleic acids (plasmid DNA, siRNA, mRNA) into cells. The positively charged headgroups of MVL-5 electrostatically bind to negatively charged nucleic acids, forming complexes called lipoplexes. The unsaturated hydrocarbon tails promote membrane fusion and facilitate cellular uptake via endocytosis. The non-degradable nature of MVL-5 provides stability for complex formation.
|
|---|---|
| ln Vitro |
MVL-5 is a highly efficient DNA and siRNA vector, demonstrating superior transfection efficiency compared to other cationic lipids in many cell types. The multivalent structure (pentavalent) allows for stronger binding to nucleic acids and more stable complex formation. MVL-5 can be used for gene delivery studies in breast cancer research, where it can deliver therapeutic genes (e.g., tumor suppressors) or siRNAs (e.g., against oncogenes) to cancer cells.
|
| ln Vivo |
MVL-5 is used in vivo as a gene delivery vehicle for pre-clinical studies. A typical protocol involves complexing MVL-5 with a therapeutic nucleic acid (e.g., a plasmid encoding a tumor suppressor gene or an anti-cancer siRNA) to form lipoplexes. The lipoplexes are then administered intravenously (e.g., via tail vein injection) or intratumorally to mice bearing subcutaneous tumors. The distribution of the nucleic acid and its therapeutic effects are assessed by measuring target gene expression, tumor growth inhibition, and signs of toxicity.
|
| Enzyme Assay |
As a transfection reagent, MVL-5 is not used in enzyme/receptor binding assays. Its ability to bind nucleic acids is assessed using an agarose gel electrophoresis retardation assay. Varying ratios of MVL-5 (0.1-10 microL) are mixed with a fixed amount of DNA or siRNA (e.g., 1 microg) in a suitable buffer (e.g., 20 mM HEPES, pH 7.4, 150 mM NaCl) and incubated at room temperature for 30 minutes. The mixtures are then loaded onto an agarose gel containing ethidium bromide and electrophoresed. Free DNA migrates into the gel, while DNA that is fully complexed with MVL-5 is retained in the wells. The complexation efficiency is determined by the disappearance of free DNA bands. Particle size and zeta potential of the lipoplexes are measured by dynamic light scattering (DLS).
|
| Cell Assay |
The cellular transfection efficiency of MVL-5 is assessed using a reporter gene assay. Cells (e.g., HeLa, HEK293, MCF-7 breast cancer cells) are seeded in 24-well or 96-well plates and grown overnight to 50-80% confluency. MVL-5 is complexed with a reporter plasmid encoding luciferase or GFP at an optimal lipid:DNA ratio (determined by the gel retardation assay). The complexes are added to the cells in serum-free medium and incubated for 4-6 hours, after which the medium is replaced with complete medium containing serum. For siRNA delivery, cells are transfected with a fluorescently labeled siRNA (e.g., Cy3-labeled siRNA) to visualize uptake, or with a functional siRNA (e.g., against a target oncogene). After 24-72 hours, luciferase activity is measured using a luminometer, GFP fluorescence is observed by microscopy or flow cytometry, or target gene knockdown is assessed by Western blot or qRT-PCR. Cytotoxicity is assessed using MTT or LDH release assays.
|
| Animal Protocol |
MVL-5 is used for in vivo gene delivery. A typical protocol involves the use of a mouse xenograft model of breast cancer (e.g., MCF-7 or MDA-MB-231 cells). MVL-5 is complexed with a therapeutic plasmid or siRNA at an optimal N/P ratio (e.g., 10:1 to 20:1, molar ratio of cationic lipid amines to nucleic acid phosphates). The lipoplex solution (e.g., 100-200 microL containing 25-50 microg of nucleic acid) is administered intravenously via tail vein injection or intratumorally on days 0, 3, and 7. Tumor volume is measured with calipers twice weekly. On study termination, tumors are harvested for analysis of target gene expression by qRT-PCR and Western blot, as well as for histopathological examination. Biodistribution of the nucleic acid is assessed by measuring labeled nucleic acid in major organs by qPCR or fluorescence imaging.
|
| ADME/Pharmacokinetics |
MVL-5 is not a therapeutic agent, and its PK properties are not studied as a free drug. When complexed with nucleic acids (lipoplexes), the pharmacokinetic properties of the complex (e.g., circulation time, biodistribution, cellular uptake) depend on the size, surface charge, and stability of the lipoplexes. MVL-5 lipoplexes typically have a particle size of 100-300 nm and a positive zeta potential, leading to rapid clearance by the reticuloendothelial system (RES) in the liver and spleen unless PEGylated or otherwise modified.
|
| Toxicity/Toxicokinetics |
MVL-5 is a cationic lipid transfection reagent and can be toxic to cells at high concentrations or with prolonged exposure. Cationic lipids can induce cellular toxicity by perturbing plasma membrane integrity, causing mitochondrial dysfunction, and activating apoptotic pathways. The non-degradable nature of MVL-5 may increase the risk of accumulation and long-term toxicity compared to biodegradable lipids. Therefore, careful optimization of lipid:nucleic acid ratios is necessary to balance transfection efficiency and cell viability. In vivo, cationic lipoplexes can activate the complement system and cause acute inflammatory responses.
|
| References | |
| Additional Infomation |
MVL-5 is a research-grade transfection reagent and is not a therapeutic drug. Multivalent cationic lipids offer advantages over monovalent lipids (e.g., DOTAP, Lipofectamine) because they can bind nucleic acids more tightly, resulting in more stable complexes and potentially higher transfection efficiency. MVL-5 is used for both DNA and siRNA delivery in gene therapy research, including cancer, genetic disorders, and infectious diseases. As of the latest updates, it has not been approved for clinical use and is exclusively available for pre-clinical research.
|
| Molecular Formula |
C59H116CL5N7O4
|
|---|---|
| Molecular Weight |
1164.86185264587
|
| Exact Mass |
1163.75
|
| CAS # |
464926-03-2
|
| PubChem CID |
155906163
|
| Appearance |
White to off-white ointment
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
53
|
| Heavy Atom Count |
75
|
| Complexity |
1180
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCC/C=C\CCCCCCCCOC1=C(C=C(C=C1)C(=O)NCCNC(=O)[C@H](CCCN(CCCN)CCCN)NCCCN)OCCCCCCCC/C=C\CCCCCCCC.Cl.Cl.Cl.Cl.Cl
|
| InChi Key |
XUWJOLKERZXVGQ-XAGHHNLJSA-N
|
| InChi Code |
InChI=1S/C59H111N7O4.5ClH/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-51-69-56-41-40-54(53-57(56)70-52-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)58(67)64-46-47-65-59(68)55(63-45-36-42-60)39-35-48-66(49-37-43-61)50-38-44-62;;;;;/h17-20,40-41,53,55,63H,3-16,21-39,42-52,60-62H2,1-2H3,(H,64,67)(H,65,68);5*1H/b19-17-,20-18-;;;;;/t55-;;;;;/m0...../s1
|
| Chemical Name |
N-[2-[[(2S)-2-(3-aminopropylamino)-5-[bis(3-aminopropyl)amino]pentanoyl]amino]ethyl]-3,4-bis[(Z)-octadec-9-enoxy]benzamide;pentahydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~85.85 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8585 mL | 4.2924 mL | 8.5847 mL | |
| 5 mM | 0.1717 mL | 0.8585 mL | 1.7169 mL | |
| 10 mM | 0.0858 mL | 0.4292 mL | 0.8585 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
